We are live on ! Find out more
CPRX icon

Catalyst Pharmaceutical

Delisted

CPRX was delisted on the 14th of July, 2026.

135 hedge funds and large institutions have $222M invested in Catalyst Pharmaceutical in 2020 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 40 increasing their positions, 50 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

1.4% less ownership

Funds ownership: 65.63% → 64.23% (-1.4%)

5% less funds holding

Funds holding: 142 → 135 (-7)

20% less repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 50

26% less call options, than puts

Call options by funds: $233K | Put options by funds: $313K

37% less capital inflows, than outflows

Capital inflows: $21.3M | Capital outflows: $34M

39% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 23

Holders
135
Holders Change
-7
Holders Change %
-4.93%
% of All Funds
2.38%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
40
Reduced
50
Closed
23
Calls
$233​K
Puts
$313​K
Net Calls
-⁠$80​K
Net Calls Change
-⁠$610​K

CPRX Hedge Fund Activity: Q4 2020 in Review

135 of the 5,678 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q4 2020, worth a combined $222M — up 10% from $202M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of CPRX and 14 opened new positions — a net loss of 9 holders — while 50 trimmed existing stakes and 40 added.

The largest buyer was Vanguard Group, adding an estimated $2.76M. The largest seller was Mangrove Partners, exiting entirely with an estimated $9M sold.

  • 135 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q4 2020, down from 142 in Q3 2020.
  • Funds reported $222M of Catalyst Pharmaceutical stock for Q4 2020, up 10% quarter-over-quarter.
  • 14 funds opened new Catalyst Pharmaceutical positions in Q4 2020 and 23 closed out, a net change of -9 holders.
  • The largest Catalyst Pharmaceutical buyer in Q4 2020 was Vanguard Group, an estimated $2.76M added.
  • The largest Catalyst Pharmaceutical seller in Q4 2020 was Mangrove Partners, an estimated $9M sold.

Based on aggregated 13F filings for Q4 2020.